9 citations
,
March 1991 in “Endocrinology” This study in rats suggests that combining the 5 alpha-reductase inhibitor 4-MA with the antiandrogen Flutamide may enhance prostate cancer therapy by additively inhibiting prostatic growth and mRNA levels of androgen-sensitive prostatic binding proteins.
49 citations
,
January 2004 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” This review discusses the development and selectivity of 5 alpha-reductase inhibitors, particularly non-steroidal ones, and reports no new clinical trial results.
45 citations
,
February 2005 in “Steroids” This study reported that certain newly synthesized steroidal derivatives showed stronger inhibitory activity against the 5α-reductase enzyme than finasteride in hamsters, suggesting their potential as enzyme inhibitors.
223 citations
,
December 2010 in “The Journal of Sexual Medicine” This review discusses persistent adverse effects of 5α‐reductase inhibitors, like diminished libido and erectile dysfunction, in some patients and highlights the need for patient discussions before therapy, especially for androgenetic alopecia.
13 citations
,
June 2018 in “Current Urology Reports” This review suggests that while finasteride for male pattern hair loss was previously considered safe, there is now evidence associating 5-α reductase inhibitors with significant sexual and reproductive side effects.